2023
DOI: 10.1016/j.pathol.2023.05.002
|View full text |Cite
|
Sign up to set email alerts
|

NTRK fusions in solid tumours: what every pathologist needs to know

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 102 publications
0
1
0
Order By: Relevance
“…Neurotrophic tyrosine receptor kinase (NTRK) and prostate-specific membrane antigen (PSMA): due to the approval of larotrectinib, an effective treatment for NTRK fusion cancers, significant progress has been made in managing cancers such as thyroid cancer, secretory carcinoma of the breast, and salivary glands ( 47 - 50 ). The assessment of NTRK fusion has now become a standard approach for managing these diseases.…”
Section: Discussionmentioning
confidence: 99%
“…Neurotrophic tyrosine receptor kinase (NTRK) and prostate-specific membrane antigen (PSMA): due to the approval of larotrectinib, an effective treatment for NTRK fusion cancers, significant progress has been made in managing cancers such as thyroid cancer, secretory carcinoma of the breast, and salivary glands ( 47 - 50 ). The assessment of NTRK fusion has now become a standard approach for managing these diseases.…”
Section: Discussionmentioning
confidence: 99%